(MENAFN- Market Press Release) November 7, 2025 5:49 am - The Whole-Exome Sequencing market, valued at USD 440.6 million in 2024, is expected to register revenue CAGR of 18.1%. Request free copy of this report:

November 07, 2025- DNA sequencing, the process of determining the precise order of nucleotides in an individual's genetic code, has revolutionized genetic research and become a vital tool for diagnosing hereditary diseases. It enables scientists and clinicians to better understand the genetic foundations of both rare and complex disorders. Whole Exome Sequencing (WES) plays a crucial role in diagnosing skeletal and muscular conditions such as muscular dystrophy and osteogenesis imperfecta by analyzing all protein-coding regions of the genome.

WES provides comprehensive insights into both germline and somatic mutations within tumor samples, offering a broader picture than targeted sequencing. It can identify low-frequency mutations that collectively contribute to complex phenotypes, making it a powerful method for understanding disease mechanisms.

In February 2025, Roche unveiled its patented Sequencing by Expansion (SBX) technology, marking a significant advancement in next-generation sequencing (NGS). When combined with a novel sensor module, SBX enables ultra-fast, high-throughput sequencing that is highly scalable and adaptable for multiple applications, including whole genome sequencing, whole exome sequencing, and RNA sequencing. This innovation represents a major step forward in precision genomics.

Despite its strengths, WES has certain limitations-such as restricted taxonomic resolution, variations in rRNA gene copy numbers, and PCR-induced biases. While amplicon-based methods are often seen as limited to detecting known variants like SNPs and InDels, they can also be used to identify broader genomic alterations beyond hotspot mutations.

Want to Know What's Fueling the Whole-Exome Sequencing Market Growth? Get Exclusive Report Insights Here:

Segments market overview and growth Insights
Based on product and service, whole-exome sequencing market is segmented into instruments, kits & consumables, software & bioinformatics solutions, and services. Instruments segment contributed the largest share in 2024. Exome sequencing, a capture-based approach, focuses on detecting genetic variations that affect protein function. Various capture methods-such as PCR, hybrid capture, and molecular inversion probes-are employed, with in-solution capture being the most efficient. This technique is especially valuable for identifying pathogenic mutations in Mendelian disorders, which are typically caused by single-gene defects.

Regional market overview and growth insights
North America held the largest market share in 2024. Market growth is primarily driven by technological advancements and the rising adoption of personalized or precision medicine. Continuous improvements in sequencing platforms are transforming diagnostic strategies across biomedical research. For instance, in October 2024, Element Biosciences launched Trinity, a breakthrough solution that streamlines target capture sequencing by reducing hybridization times and simplifying workflows on the AVITI System, without compromising cost or quality.

Competitive Landscape and Key Competitors
The Whole-Exome Sequencing market is characterized by a fragmented structure, with many competitors holding a significant share of the market. List of major players included in the Whole-Exome Sequencing market report are:

oIllumina, Inc.
oIntegrated DNA Technologies, Inc
oCD Genomics
oCENTOGENE GmbH
oCaris Life Sciences
oThermo Fisher Scientific Inc.
oCelemics, Inc.
oPreventionGenetics
oF. Hoffmann-La Roche Ltd
oQIAGEN
oGENEWIZ from Azenta
oSource BioScience
oAdmera Health
oTwist Bioscience

Buy Your Exclusive Copy Now:

Major strategic developments by leading competitors
Almac Diagnostic Services: In August 2023, Almac Diagnostic Services expanded its NGS capabilities after installing the first Illumina NovaSeq X Plus instrument in Northern Ireland, enhancing sequencing capacity for BioPharma clients.

QIAGEN: In January 2023, QIAGEN entered an exclusive strategic partnership with Helix, a leader in population genomics, to advance companion diagnostics for genetic disorders. This collaboration leverages Helix's FDA-approved whole exome sequencing platform, marking another milestone in next-generation genomic analysis.

Unlock the Key to Transforming Your Business Strategy with Our Whole-Exome Sequencing Market Insights –
.Download the report summary:
.Request customization:

Navistrat Analytics has segmented the Whole-Exome Sequencing market based on product and servicr, technology, application, end-use, and region:
.Product and Service Outlook (Revenue, USD Million; 2022-2032)
oInstruments
oKits & Consumables
oSoftware & Bioinformatics Solutions
oServices

.Technology Outlook (Revenue, USD Million; 2022-2032)
oSequencing Platforms
oExome Capture Methods

.Application Outlook (Revenue, USD Million; 2022-2032)
oClinical Diagnostics
oDrug Discovery & Development
oPopulation Genomics & Translational Research
oAgrigenomics / Veterinary Research

.End-Use Outlook (Revenue, USD Million; 2022-2032)
oHospitals & Clinical Diagnostic Laboratories
oAcademic & Research Institutes
oPharmaceutical & Biotechnology Companies
oContract Research Organizations (CROs)
oGovernment & Public Health Programs

.Regional Outlook (Revenue, USD Million; 2022-2032)
oNorth Benelux
g Countries
h of Europe
oAsia Pacific
a Japan
d Oceania
f Countries
g of APAC
oLatin Brazil
b of LATAM
oMiddle East & Africa
a Countries
b Turkey
e of MEA

Get a preview of the complete research study:

About Us:
At Navistrat Analytics, we provide high-quality, comprehensive syndicated and customized market research reports that deliver actionable insights and empower businesses through data-driven strategies. Choose Navistrat Analytics as your strategic growth partner for reliable market intelligence, and let us help you navigate the complexities of the market with clarity, precision, and confidence.

Contact Us:
Navistrat Analytics
Visit Us:
Email Us:...
Asia-Pacific: +91-9073010653
Follow Us LinkedIn:

MENAFN09112025003520003262ID1110315756